Glaucoma - Epidemiology Forecast - 2034

Glaucoma - Epidemiology Forecast - 2034

Key Highlights

DelveInsight's analysts project that in the 7MM, around 42% of the total prevalent cases of Glaucoma are diagnosed, owing to factors such as aging populations and enhanced diagnostic techniques facilitating early detection.

Approximately 7 million cases of the total diagnosed prevalent cases of glaucoma was estimated in the 7MM in 2023 and indicated to increase in the study period.

DelveInsight's estimates indicate that in 2023, there were approximately 2.5 million diagnosed prevalent cases of glaucoma in the US, around 3 million in EU4 and the UK combined, and roughly 1.6 million in Japan.

DelveInsight’s “Glaucoma – Epidemiology – 2034” report delivers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Diagnosis Algorithm

Glaucoma Overview

Glaucoma, a condition affecting the optic nerve due to fluid buildup in the eye, elevates intraocular pressure and causes damage. It stands as a primary cause of blindness among adults over 60. Two main forms, primary open-angle glaucoma (POAG) and angle-closure glaucoma (OAG), exist. Normal-tension glaucoma may also occur without noticeable symptoms initially, leading to gradual blurry vision and eventual side vision loss. Symptoms of POAG include patchy blind spots in peripheral vision progressing gradually, while OAG symptoms involve eye redness, headaches, nausea, and blurred vision. In children, symptoms such as increased blinking, blurred vision, and headaches may indicate glaucoma, while pigmentary glaucoma presents with light-related halos and exercise-induced vision problems alongside progressive side vision loss.

Glaucoma Diagnosis

A thorough eye exam and a number of specific tests, such as tonometry (measurement of intraocular pressure), an ophthalmoscopy (examination of the optic nerve for signs of damage), visual field testing (perimetry), and gonioscopy (assessment of the drainage angle of the eye to determine the type of glaucoma) are usually performed, to diagnose glaucoma. Also, the optic nerve's health and IOP levels are assessed. Early detection through regular eye exams is crucial as treatment aims to lower intraocular pressure to prevent further damage and prevent irreversible vision loss.

Further details related to diagnosis are provided in the report…

Glaucoma Epidemiology

As the epidemiology is derived using the patient-based model, the Glaucoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total prevalent Cases of Glaucoma, Total diagnosed prevalent cases of Glaucoma, Type-specific Diagnosed Prevalent Cases of Glaucoma, Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma, Gender-specific Diagnosed Prevalent Cases of Glaucoma and the Age-specific Diagnosed Prevalent Cases of Glaucoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034. As per DelveInsight’s estimations, the total diagnosed prevalent cases of Glaucoma in the 7MM were approximately 7 million cases in 2022 and are projected to increase during the forecast period.

Glaucoma is considered one of the leading causes of irreversible blindness in the country. The analyzed glaucoma prevalent cases from the total US population in 2023 were estimated to be approximately 5 million and is forecasted to rise by 2034.

Among EU4 and the UK, Germany had the highest diagnosed prevalent population of glaucoma, with 0.7 million cases, followed by France and Italy in 2023. On the other hand, Spain had the lowest diagnosed prevalent population in the European region in 2023.

Glaucoma is broadly categorized into two primary types: open-angle glaucoma (OAG) and angle-closure (closed-angle) glaucoma (ACG). Of all the diagnosed glaucoma cases in the US, it was estimated that open-angle glaucoma cases was around 2.3 million in 2023, while closed-angle glaucoma cases was 0.3 million.

DelveInsight's epidemiology model for glaucoma classifies open-angle glaucoma into subtypes based on various clinical features. In 2023, there were around 2 million cases of primary open-angle glaucoma (POAG), 0.8 million cases of normal tension glaucoma (NTG), and 0.2 million cases of secondary open-angle glaucoma (SOAG).

Glaucoma can affect both males and females, but certain studies have reported differences in prevalence between the genders. Women bear a greater burden than men.

As per DelveInsight’s analysis, diagnosed prevalent cases of glaucoma based on age were categorized into three groups, 2–17 years, 18–39 years, and 40 years and above. The age group 40 years and above accounted for highest among all age group with 6.6 million cases in the 7MM in 2023.

Among the 7MM, Japan reported around 1.6 million cases diagnosed prevalent cases of glaucoma in 2023.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Glaucoma evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from Duke University Eye Center, Durham, North Carolina; Centre Hospitalier National d'Ophtalmologie, Paris, France; University of Genova, Italy; University Hospital of Albacete & Quironsalud, Albacete, Spain; European Board of Ophthalmology; Department of Ophthalmology, Kyushu University, Fukuoka, Japan; and others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Glaucoma, explaining its causes, signs and symptoms, and pathogenesis.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Glaucoma Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total prevalent Cases of Glaucoma

Total diagnosed prevalent cases of Glaucoma

Type-specific Diagnosed Prevalent Cases of Glaucoma

Type-specific Diagnosed Prevalent Cases of Open-angle Glaucoma

Gender-specific Diagnosed Prevalent Cases of Glaucoma

Age-specific Diagnosed Prevalent Cases of Glaucoma

Glaucoma Report Key Strengths

11 years Forecast

The 7MM Coverage

Glaucoma Epidemiology Segmentation

Key Questions

Epidemiology Insights

What are the disease risks, burdens, and unmet needs of Glaucoma? What will be the growth opportunities across the 7MM concerning the patient population of Glaucoma?

What is the historical and forecasted Glaucoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

Why do only limited patients appear for diagnosis?

Which country is more prevalent for Glaucoma and why?

What factors are affecting the diagnosis of the indication?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Glaucoma prevalence cases in varying geographies over the coming years.

A detailed overview of Severity, Gender, and Age-specific prevalence of Glaucoma.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Glaucoma Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Glaucoma cases in 2023?

The highest cases of Glaucoma was found in the France, among EU4 and the UK, in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Glaucoma cases in 2023?

The highest cases of Glaucoma were found in the US among the 7MM in 2023.